ABUS vs BLK · P/E 5.4, rev $6.2M vs P/E 27, rev $24.22B
Arbutus Biopharma Corp (ABUS) versus BlackRock Inc (BLK) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
BlackRock Inc (BLK) is a asset management company listed on NYSE. It is led by Larry Fink.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported BLK revenue for 2025-12-31 was $24.22B. Net income was $5.55B. Revenue was up 89.3% from 2024-12-31 to 2025-12-31. BLK currently screens at market cap $172.19B and trailing P/E 26.6.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. BLK currently screens at market cap $172.19B and trailing P/E 26.6.
Not investment advice. Open the ABUS and BLK stock pages for the full models.
Not investment advice.